Resources
Application Form C – Change of details – Inborn Errors of Metabolism
Form
Individuals registered with the Inborn Errors of Metabolism program can use this form to change their personal information.
Application Form A for Conditions Group 1 – Inborn Errors of Metabolism
Form
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism — DHPR, hyperphenylalaninemia and PKU conditions only. For other conditions, use Application Form B.
Application Form B for Conditions other than Group 1 – Inborn Errors of Metabolism
Form
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism (other than DHPR, hyperphenylalaninemia and PKU).
Application to register as an Approved Metabolic Specialist – Inborn Errors of Metabolism
Form
Specialist doctors can use this form to apply for registration as an approved metabolic specialist under the Inborn Errors of Metabolism (IEM) program.
Centre for Disease Control stakeholder consultation report
Report
This report summarises stakeholder responses to the Role and functions of an Australian Centre for Disease Control (CDC) consultation paper.
National Action Plan for Endometriosis
Report
This National Action Plan for Endometriosis acknowledges that endometriosis causes a substantial health burden in Australia. It sets goals and objectives to address this burden.
Endometriosis Progress Report 2023
Report
The Australian Government is taking active steps to address the significant burden that endometriosis is placing on Australian women. Since the release of the National Action Plan for Endometriosis in July 2018 several projects including research opportunities have been successfully implemented.
Making a claim to the HCAF fact sheet
Fact sheet
This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.
Acute rheumatic fever and rheumatic heart disease – CDNA National Guidelines for Public Health Units
Guideline
These guidelines for Public Health Units provide nationally consistent guidance on how to respond to acute rheumatic fever (ARF) and rheumatic heart disease (RHD). They are part of a Series of National Guidelines (SoNGs) published by the Communicable Diseases Network Australia (CDNA).
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Reapplication
Form
Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.
Last updated:
Tags: